Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Transcenta
Suzhou, Jiangsu, China
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Transcenta is a clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics. The company focuses on oncology, nephrology, and bone diseases, leveraging its proprietary Integrated Continuous Bioprocessing (ICB) platform to significantly reduce manufacturing costs and improve efficiency. Its lead candidate, Osemitamab (TST001), is a high-affinity humanized Claudin 18.2-targeting antibody currently in global Phase 3 trials for gastric cancer. Transcenta maintains a global presence with R&D and manufacturing facilities in Suzhou and Hangzhou, China, and clinical operations in Princeton, New Jersey.
- Therapeutic areas
- OncologyEndocrinologyNephrology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateRecombinant fusion protein
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Suzhou Transcenta.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Transcenta.